1000/1000
Hot
Most Recent
The discovery of antibiotics has revolutionized the medicine and treatment of microbial infections. However, the current scenario has highlighted the difficulties in marketing new antibiotics and an exponential increase in the appearance of resistant strains. Here, the main antibiotic resistance mechanisms are briefly listed with some examples.
Biologically active molecules are defined as antimicrobials if they are able to inhibit growth or to kill certain or various classes of microorganisms. However, microorganisms have developed several mechanisms to circumvent the action of these antimicrobial compounds. In this context, it is worthwhile to specify the difference between antimicrobial resistance and persistence. Resistance to a given molecule is maintained from the mother cell to the daughter cells, unless mutations make them susceptible again [1]. In comparison, persistence is defined as the ability of microbial cells to be recalcitrant to the antibiotic action, as they enter into a stationary phase of their growth (dormant cells). This leads to the inefficacy of the antibiotic agents since most of them act by inhibiting or interacting with specific metabolic processes that are not active in dormant cells [2][3]. It is also important to define the two major types of antimicrobial resistance: natural and acquired [4][5]. Natural resistance can be constantly expressed in the bacterial species (intrinsic resistance), whereas acquired resistance is expressed only upon exposure to an antimicrobial agent (induced resistance) [6]. The reduced permeability of the outer membrane and the activity of efflux pumps are classic examples of intrinsic resistance [7]. Acquired resistance occurs through acquisition of genetic material by means of transformation, conjugation, transposition (horizontal gene transfer) or by mutation in the chromosomal DNA [8][9]. Mutation of the drug target or in those genes involved in the regulation of drug transporters are examples of acquired resistance [4].
Gram(+) and Gram(−) bacteria possess and/or have developed several mechanisms of antimicrobial resistance that fall into five major categories (Figure 1):
Limitation of drug uptake. Bacteria can be intrinsically resistant to a certain antimicrobial due to their structure and morphology. Lipopolysaccharide (LPS) in Gram(−) bacteria, for example, provides a physical barrier that protects the cell from several groups of large molecules [10]. In these bacteria, drugs are internalized through porin channels that generally allow the uptake of hydrophilic molecules. Mutations that change their selectivity or that reduce the number of expressed porins are the two major mechanisms of antimicrobial resistance [11][12]. Gram(+) bacteria, lacking outer membrane, possess a peptidoglycan cell wall and the restricting drug uptake is not as prevalent. However, pathogenic bacterial species, i.e., Staphylococcus aureus, have developed a mechanism which consists in thickening the cell wall to limit the amount of drug that enters the cell [13][14]. Mycoplasma spp, devoid of cell wall, are intrinsically resistant to antimicrobials (e.g., β-lactams and glycopeptides) that interfere with cell wall synthesis and regulation [15].
Drug inactivation. Bacteria can produce several enzymes or molecules that inactivate drugs by covalent binding or enzymatic processes. Firstly, common antibiotics (e.g., aminoglycosides, streptogramins, fluoroquinolones, chloramphenicol) could be inactivated by acetylation, phosphorylation or adenylation; secondly, hydrolyzation is the primary mechanism by which bacteria can inactivate β-lactam antibiotics (e.g., cephalosporins, penicillins and cephamycins). β-lactamases are the most common example: these enzymes provide resistance to β-lactam antibiotics by hydrolyzing a specific site in the β-lactam ring structure [16]. Recently, β-lactamases were found to be active against carbapenems in Enterobacteriaceae (carbapenemases, i.e., Klebsiella pneumoniae carbapenemases and carbapenem-resistant enterobacteriaceae enzymes) [16].
Mutation/alteration of the drug target. The majority of antimicrobials have a specific mechanism of action against a specific cellular target and this is one of the reasons why bacteria are not susceptible to a certain class of molecules [17]. Gram(+) strains, for instance, become resistant to β-lactam drugs via alteration of the penicillin-binding proteins, that are transpeptidases involved in the cell wall construction [18]. S. aureus acquires resistance to the glycopeptide vancomycin by decreasing the binding ability of this molecule to the cell wall, as a consequence of a modification of the terminal d-Ala–d-Ala moiety of the peptidoglycan precursor lipid II [19].
Drug efflux. Bacteria can eliminate internalized toxic substances through a mechanism involving efflux pumps, which can be constitutively expressed or overexpressed under certain conditions. Many of these pumps have the capability to transport different types of substances. They are properly named multi-drug efflux pumps [20] and their increased number is generally associated to high-level of resistance to clinically significant bacterial infections [21][22].
Biofilm formation. In conditions of environmental stress, scarcity of nutrients, presence of antimicrobial molecules, some bacterial species can switch from a motile to a sessile lifestyle, named biofilm. This is a bacterial community able to colonize abiotic (e.g., medical devices and implants [23][24][25]) and biotic surfaces (e.g., human tissues [26][27][28]). Biofilm formation is a strategy used by pathogenic bacteria to protect themselves from the external stressful conditions by producing a thick and sticky extracellular matrix which contains DNA, proteins and polysaccharides. In addition, biofilm cells enter into a slow division rate, which weakens the effect of antibiotic molecules targeting specific cellular processes. Thus, biofilms are often associated to chronic infections and molecules capable to disrupt these communities and/or to inhibit their formation are highly demanded [29][30].
Figure 1. Schematic representation of the principal mechanisms of antibiotic resistance.